Combined WNT-activated deep-penetrating/plexiform melanocytoma: insights into clinicopathological and molecular characterization
Clinical and Experimental Dermatology · 2024
DOI: 10.1093/ced/llad405 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2024. Verfasst von Paola Castillo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Pathology. Hauptthemen laut MEDLINE: Melanoma, Nevus, Epithelioid and Spindle Cell, Skin Neoplasms, Succinimides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Background
A combined deep-penetrating tumour redefined as WNT-activated deep-penetrating/plexiform melanocytoma (DPM), may pose challenging clinical and histological diagnoses.
Objectives
To review the clinicopathological characteristics of combined DPMs and characterize the molecular profile of atypical and malignant forms.
Methods
The study included 51 patients with combined DPMs diagnosed at the Hospital Clinic of Barcelona and the University of Florence between 2012 and 2020. Clinical data, dermoscopy images (when available) and histological characteristics were reviewed. Immunohistochemistry for β-catenin, LEF1, HMB45, Ki67, p16 and PRAME (preferentially expressed antigen in melanoma) was performed. Atypical forms underwent next-generation sequencing (NGS) panel analysis, including driver genes implicated in DPMs, TERT-promoter (p) mutations and the investigation of the 9p21 locus via fluorescence in situ hybridization.
Results
Among the 51 patients (32 females and 19 males, age range 4–74 years), 68% with available clinical data (15/22) were initially suspected of having melanoma. Except for one patient, complete excision resulted in no recurrences or metastases. One patient who had an incompletely excised combined DPM developed a lymph node melanoma metastasis 10 years later. In the 51 patients, 10 samples (20%) showed atypical histological features; 7 (14%) exhibited a significant loss of p16 expression; and 2 (4%) showed a high-proliferative index (Ki67 over 5%). NGS analysis in 11 patients revealed a double mutation BRAFV600E and exon 3 CTNNB1; no TERTp mutations were detected.
Conclusions
Clinical suspicion of melanoma is common in combined DPMs, but malignant progression is infrequent in tumours lacking high-grade atypia or proliferation. These findings are congruent with the consideration of these lesions as intermediate-grade tumours or melanocytomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departments of Pathology.
- University of Barcelona. Barcelona, Spain.
- August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
- Section of Anatomical Pathology, Department of Health Sciences, University of Florence. Florence, Italy.
- European Organisation for Research and Treatment of Cancer (EORTC), Melanoma Group.
- Dermatology.
ORCID-Profile: Paola Castillo, Susana Puig, Llucia Alos
Zitieren
APA
Castillo, P., Castrejon, N., Marginet, M., Massi, D., Alamon, F., Teixido, C., Montironi, C., Garcia-Herrera, A., Albero-Gonzalez, R., Matas, J., Puig, S., & Alos, L. (2024). Combined WNT-activated deep-penetrating/plexiform melanocytoma: insights into clinicopathological and molecular characterization. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad405
Vancouver
Castillo P, Castrejon N, Marginet M, Massi D, Alamon F, Teixido C, et al. Combined WNT-activated deep-penetrating/plexiform melanocytoma: insights into clinicopathological and molecular characterization. Clinical and Experimental Dermatology. 2024. doi:10.1093/ced/llad405
BibTeX
@article{Castillo2024,
author = {Castillo, Paola and Castrejon, Natalia and Marginet, Marta and Massi, Daniela and Alamon, Francesc and Teixido, Cristina and Montironi, Carla and Garcia-Herrera, Adriana and Albero-Gonzalez, Raquel and Matas, Jessica and Puig, Susana and Alos, Llucia},
title = {Combined WNT-activated deep-penetrating/plexiform melanocytoma: insights into clinicopathological and molecular characterization},
journal = {Clinical and Experimental Dermatology},
year = {2024},
doi = {10.1093/ced/llad405}
}
EUVIMED